✦ LIBER ✦

More Than Attendance: The Importance of After-School Program Quality

✍ Scribed by Barton J. Hirsch; Megan A. Mekinda; JulieAnn Stawicki

Publisher: Springer US
Year: 2010
Tongue: English
Weight: 144 KB
Volume: 45
Category: Article
ISSN: 0091-0562
DOI: 10.1007/s10464-010-9310-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

After-school program attendance and the

After-school program attendance and the social development of rural latino children of immigrant families

✍ Nathaniel R. Riggs 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

The Relative Importance of Provider, Pro

The Relative Importance of Provider, Program, School, and Community Predictors of the Implementation Quality of School-Based Prevention Programs

✍ Allison Ann Payne; Ronald Eckert 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 269 KB

Engagement in after-school program activ

Engagement in after-school program activities: quality of experience from the perspective of participants

✍ David Jordan Shernoff; Deborah Lowe Vandell 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 223 KB

A method for evaluating research synthes

A method for evaluating research syntheses: The quality, conclusions, and consensus of 12 syntheses of the effects of after-school programs

✍ Jeffrey C. Valentine; Harris Cooper; Erika A. Patall; Diana Tyson; Jorgianne Civ 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt